Mobic (meloxicam) Tablets
Company: Boehringer Ingelheim
Approval Status: Approved April 2000
Treatment for: For relief of the signs and symptoms of osteoarthritis
Areas: Musculoskeletal; Rheumatology
| General Information | Clinical Results | Side Effects | Mechanism of Action | Additional Information |
General Information
Mobic is a once-daily, 7.5 mg tablet indicated for the relief of the pain and stiffness associated with osteoarthritis. Mobic is a non-steroidal anti-inflammatory drug (NSAID).
Osteoarthritis is a disease which affects approximately 80% of Americans over the age of 65. The disease, which causes the cartilage in the joints to break down, is especially painful and debilitating.
Clinical Results
A double-blind, controlled study was conducted in the U.S. to evaluate the safety and efficacy of Mobic. The 12-week study involved 464 patients who had osteoarthritis of the knee and hip. When three different doses of Mobic (3.5 mg, 7.5 mg, and 15 mg daily) were compared to placebo, results indicated that both the 7.5 and 15 mg daily doses of Mobic significantly decreased symptoms of pain, function, and stiffness in patients, with a low incidence of gastrointestinal side effects.
Six similar studies were conducted outside of the U.S. Results were consistent with those found in the U.S. study.
Side Effects
Although Mobic tablets are generally well-tolerated gastrointestinally, gastrointestinal ulcers may develop without warning symptoms. While taking Mobic, specific attention should be paid to any sign of gastrointestinal bleeding.
Do not use Mobic if:
- you have a known allergy to meloxicam, aspirin or other NSAIDs
- you are, or may be, pregnant
Mechanism of Action
Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) that
exhibits anti-inflammatory, analgesic, and antipyretic activities
in models. The mechanism of action of meloxicam, like that of other
NSAIDs, may be related to prostaglandin synthetase (cyclooxygenase)
inhibition.
(From FDA Label)
Additional Information
Mobic, which will be marketed jointly in the U.S. by Boehringer Ingelheim Pharmaceuticals, Inc. and Abbott Laboratories, will be priced approximately 20% less than some other osteoarthritis drugs in its class.
Visit the Boehringer Ingelheim Pharmaceuticals, Inc. web site to learn more about Mobic and about other products, research, and services provided by the company that developed this drug.
For more information about osteoarthritis and research and treatments in this field, visit the web site of the Arthritis Foundation: www.arthritis.org
The FDA drug information shown here is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.
